MEI Pharma (DB:MMI0) - Hisse Senedi Fiyatı, Haberler ve Analizler

MMI0 Stoklara Genel Bakış

A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. Daha fazla detay

MMI0 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 4% oranında düşmesi öngörülüyor

Anlamlı bir piyasa değeri yok ( €50M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

MEI Pharma, Inc. Rakipler

Heidelberg Pharma

XTRA:HPHA

€101.1m

2invest

XTRA:2INV

€62.7m

Medigene

XTRA:MDG1

€23.7m

co.don

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti MEI Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.20
52 Haftanın En Yüksek Seviyesi	US$11.40
52 Haftanın En Düşük Seviyesi	US$3.58
Beta	0.92
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-63.79%
33 Yıllık Değişim	-93.14%
5 Yıllık Değişim	-93.84%
Halka arzdan bu yana değişim	-96.40%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MMI0	DE Biotechs	DE Pazar
7D	0%	0.8%	-1.3%
1Y	-63.8%	-17.5%	7.4%

Getiri vs. Endüstri: MMI0 geçen yıl % -17.5 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: MMI0 geçen yıl % 7.4 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MMI0's price volatile compared to industry and market?
MMI0 volatility
MMI0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: MMI0 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MMI0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	102	David Urso	meipharma.com

MEI Pharma, Inc. Temel Bilgiler Özeti

MEI Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MMI0 temel i̇stati̇sti̇kler
Piyasa değeri	€44.15m
Kazançlar(TTM)	-€33.73m
Gelir(TTM)	€52.34m

0.8x

P/S Oranı

-1.3x

F/K Oranı

MMI0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MMI0 gelir tablosu (TTM)
Gelir	US$58.77m
Gelir Maliyeti	US$0
Brüt Kâr	US$58.77m
Diğer Giderler	US$96.65m
Kazançlar	-US$37.87m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.68
Brüt Marj	100.00%
Net Kâr Marjı	-64.44%
Borç/Özkaynak Oranı	0%

MMI0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MMI0 Stoklara Genel Bakış

Ödüller

Risk Analizi

MEI Pharma, Inc. Rakipler

XTRA:HPHA

€101.1m

XTRA:2INV

€62.7m

XTRA:MDG1

€23.7m

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

Recent updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Insufficient new directors

Second quarter 2023 earnings released: EPS: US$0.077 (vs US$0.096 loss in 2Q 2022)

Insufficient new directors

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.17 loss in 1Q 2022)

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Full year 2022 earnings released: US$0.44 loss per share (vs US$0.37 loss in FY 2021)

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Forecast to breakeven in 2024

Forecast to breakeven in 2024

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director recently sold €83k worth of stock

New 90-day high: €3.28

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

Revenue beats expectations

New 90-day high: €2.52